片语

overall survival after hepaticmetastasis期及出现肝转移后生存

overall survival e总生存率

overall survival OS总生存期

OS-Overall Survival总生存期

median overall survival time位生存期

overall survival rates总生存率

overall survival rate总生存率

overall survival time时间

英汉例句

• overall survival and progression-free survival also did not differ in the two groups, the researchers note.

  研究人员提到，在两组中总生存期和无进展生存也没有差异。

• among the 12 study participants with breast cancer, the median time before the disease continued to progress was 2.5 months and the median overall survival was 13.7 months.

  在12个乳腺癌患者的调查中，疾病至进展期的中位时间是2.5个月，中位总生存期是13.7个月。

• therefore, a small (but potentially important) difference in overall survival between wide and narrow excision margins cannot be confidently ruled out.

  因此，这一小部分 （但潜在重要） 的差异，存在于宽范围和窄范围切除间的整体存活率的差异，不能确信地排除。

• a limited number of genes were related to overall survival and cancer-free survival after lt.

  有限数目的基因和全部生存率和肝移植后无癌生存率相联系。

• while the time before disease progression was similar between patients who did and did not receive the vaccine, the overall survival time in the vaccine group was 「strikingly better,」 he noted.

  接受疫苗注射和未接受者至疾病进展期类似，但他特别强调，总生存期则有了很大的改善。

• 「females had significantly better overall survival than males, except in patients aged 1 to 9 years, 」 the investigators found.

  研究者发现，除了1到9岁的患者，女性患者整体存活率显着高于男性患者。

• in compare of mc patients with sr tumors were worse in long-term overall survival , survival in the group of receiving radical resection. (p0.05).

  印戒细胞癌与黏液腺癌总体存活率相比差异有统计学意义（p根治手术组总体存活率相比差异有统计学意义（p0.05）。

• median survival reflects one time point along the survival curve and does not measure the overall survival benefit.

  生存中值反映了生存曲线上的一个时间点，并不能测量总的生存期。

• he cited the asco guidelines on hormonal therapy that stated that there is a 15-17% cancer specific survival, but is no overall survival benefit.

  他引用了美国临床肿瘤学会激素治疗指南，其中提及仅有15-17％癌癥相关生存率但没有总生存期获益。

• this cancer often is not found until it is advanced or has spread, and overall survival is dismal: 20 percent after one year and only 4 percent after five years.

  胰腺癌很难前期诊断，通常发现患病时，病情已经处在癌癥晚期或扩散阶段，并且患者的平均存活率很低:确诊一年后大约为20%的存活率,确诊五年后只有大约4%的存活率。

• overall survival of our patients was 67.6%.

  分析结果如下：病人的总存活率为67.6%。

• the overall survival ranges from less than one year to 10+ years from the discovery of the metastasis and is similar in both tumor subtypes.

  颅底转移患者总的存活时间范围从不到1年到10年不等，且与原发癌的相应亚型生存时间类似。

• conclusions the igs is strongly associated with metastasis-free survival and overall survival for four different types of tumors.

  结论：在四种不同类型的肿瘤中，igs和无转移生存期以及总体生存期紧密相关。

• overall survival was much higher in patients treated with asa404.

  使用asa404者总体生存率比较高。

• the median pfs was 11 months and the median overall survival (os) was 20.3months.

  中位无进展生存期是11个月，中位总生存率是20.3个月。

• most children diagnosed with cancer now survive -- the overall survival beyond five years for pediatric cancer is more than 70 percent.

  随着医学技术的进步，大多数被确诊罹患癌癥的孩子最终均可战胜病魔。儿童癌癥患者的5年以上存活率目前已超过70％。

• patients who received pemetrexed had an overall survival of 13.4 months, versus 10.6 months for patients in the placebo group.

  接受培美曲塞治疗的患者总体生存期为13.4个月，比较于安慰剂组的10.6个月。

• for the 14 patients with ovarian cancer, the median time to progression was two months and the median overall survival was 15 months.

  14个卵巢癌患者调查中，疾病知进展期中位时间是2个月，中位总生存期是15个月。

• as noted, however, no significant difference in overall survival was seen between the groups, with a median survival period for each of about 26 months.

  然而，正如已经提到的，在各组之间没有看到总体存活率的显着性差异，中值存活期分别为约26个月。

• nodal status correlates with disease-free and overall survival better than other prognostic factors.

  与其他预后因素相比，结节状况与无病及总存活率关系更大。